PharmSight Strengthens Global Footprint with New Office in Zug (Switzerland); Launches Conversity’s AI Training Platform
17.6.2025 09:30:00 EEST | Business Wire | Press release
PharmSight Research & Analytics today announces the opening of its European hub in Zug, Switzerland. Operating as PharmSight GmbH, this strategic expansion reinforces the company’s commitment to deliver data-driven insights for negotiation training, sales force optimization, and market access solutions in the heart of Europe’s pharmaceutical ecosystem.
Leading PharmSight GmbH is Mr Gianclaudio Floria, recently appointed CEO with over 20 years of experience in commercial operations and strategic roles at industry giants like Amgen, BMS, Fresenius Kabi, Gilead, and Alexion. A published author and recognized thought leader, Mr. Floria brings extensive international expertise in Finance, M&A, Strategic Planning, and Market Access, reinforcing PharmSight’s vision for Europe.
A cornerstone of the Zug launch is the debut of Conversity, an AI-driven training platform that leverages ultra-realistic avatars, scenario-based simulations, and real-time analytics to elevate negotiation and sales performance. Conversity helps professionals navigate complex agreements, optimize market access, and refine sales engagement. With this addition to its European portfolio, PharmSight further cements its role as a trusted partner in the region’s pharmaceutical landscape.
“Our Zug office marks a significant step in our global journey,” said Siddharth Pathela, Co-founder of PharmSight. “We’re excited to unveil Conversity, the latest addition to our proprietary AI toolkit – Intellisight, Pharmlens, Pharmalert, and Cintel. Conversity is set to transform negotiation and sales training, delivering strong value to the biopharma sector.”
This milestone follows PharmSight’s recent launch in the U.S. market. With offices in Boston and now Zug, PharmSight is planning expansion into the Middle East and establishing an innovation center focused on AI/ML.
About PharmSight
PharmSight is a global consulting firm serving the biopharmaceutical industry through advanced data management and analytics, forecasting, CI, HEOR, reporting automation, patient analytics, and AI-driven solutions. Headquartered in Gurugram, India, with offices in Boston and Zug, PharmSight’s 50+ consultants collaborate with clients worldwide to transform data into actionable insights.
About Conversity
Conversity is an AI-powered negotiation training platform designed specifically for the pharmaceutical sector. With its immersive simulations, customized scenarios, and in-depth analytics, Conversity equips professionals to master negotiation skills, enhance market access, and achieve superior sales performance.
For more information, please visit www.pharmsight.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616604727/en/
Contacts
Gianclaudio Floria
g.floria@pharmsight.com
Rachit Syag
Rachit@pharmsight.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom